早期高危宫颈鳞癌患者术后同步放化疗后巩固化疗的临床疗效  

Clinical efficacy of consolidation chemotherapy following concurrent chemoradiotherapy after rad-ical surgery on patients with high-risk early stage cervical squamous cancer

作　　者：李白羽 刘明博 王跃伟 王伟 李会荣 刘建波 

机构地区：[1]河南省人民医院郑州大学人民医院放疗科,郑州450003

出　　处：《中国实用医刊》2017年第24期27-30,共4页Chinese Journal of Practical Medicine

摘　　要：目的 探讨早期高危宫颈鳞癌患者术后同步放化疗后巩固化疗的疗效和毒副反应.方法 135例ⅠB1- ⅡA期（FIGO 2009）根治术后有高危因素的宫颈鳞癌患者分为巩固组（68例）和观察组（67例）,观察组仅给予顺铂同步放化疗,巩固组同步放化疗后行＂多西他赛（DTX）75 mg/m2（第1天）＋顺铂（DDP）75 mg/m2（第1-3天）＂方案化疗3个周期,化疗周期为21 d.随访3年,观察患者总生存率（OS）及不良反应.结果 巩固组和观察组患者3年总生存率分别为88.0％、71.4％,P=0.03.两组患者的不良反应发生率比较,差异未见统计学意义.结论 早期高危宫颈鳞癌患者术后同步放化疗后巩固化疗可提高患者总生存率,并且患者耐受良好.Objective To investigate the curative effect and toxicity of consolidation chemothera-py following concurrent chemoradiotherapy after radical surgery on patients with high-risk early stage cer-vical squamous cancer. Methods A total of 135 high-risk patients with clinical FIGO 2009 stage ⅠB1 -ⅡA who had undergone radical surgery were divided into consolidation group（68 cases）and observation group（67 cases）. The patients in the observation group were treated with DDP concurrent chemoradio-therapy alone,while in the consolidation group,DTX 75 mg / m2 （d1）,and DDP 75 mg / m2 （d1 - 3）were given every three weeks for 3 cycles. The endpoint was OS,toxic and side effect. Results The 3-year o-verall survival rate were 88. 0% and 71. 4%,respectively,（P = 0. 03）;there was no significant differ-ence in the incidence of grade 3 or 4 reactions between the two groups（P 〉 0. 05）. Conclusions The consolidation chemotherapy after CCRT following radical surgery may improve overall survival,and it is well tolerated for patients with high-risk early stage cervical cancer.

关 键 词：高危早期宫颈鳞癌 巩固化疗 同步放化疗 疗效 不良反应 

分 类 号：R737.33[医药卫生—肿瘤]